Disease · HP_0001072
Thickened skin
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Thickened skin. Diseases, record HP_0001072. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001072
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Thickened skin
- Open Targets ID
- HP_0001072
- Other names
- Pachydermia, Thick skin
- Highest stage of its drugs
- Phase 2, for 3 of its 7 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ABATACEPT | CHEMBL1201823 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ILOPROST | CHEMBL494 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IMATINIB | CHEMBL941 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BETAMETHASONE VALERATE | CHEMBL1497 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLOBETASOL PROPIONATE | CHEMBL1159650 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROCORTISONE ACETATE | CHEMBL1091 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PIMECROLIMUS | CHEMBL1200686 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 1 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 2 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 2 | https://conductscience.org/library/genes/942 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 1 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 1 | Platelet-derived growth factor receptor beta inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| PTGIR | Prostacyclin receptor | 1 | Prostanoid IP receptor agonist | Phase 2 | https://conductscience.org/library/genes/5739 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02161406 | A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis | Phase 2 | 88 | 2019-06-18 | Diffuse Cutaneous Systemic Sclerosis | ABATACEPT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00555581 | Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis | Phase 2 | 30 | 2018-02-06 | Systemic Sclerosis | IMATINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00442611 | A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) | Phase 1/2 | 10 | 2015-04-24 | Scleroderma, Diffuse, Scleroderma, Systemic | ABATACEPT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00622687 | Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis | Phase 2 | 50 | Systemic Sclerosis | ILOPROST | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00655512 | Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound | Phase 1 | 40 | Healthy | BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, HYDROCORTISONE ACETATE, PIMECROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Abatacept vs Placebo: deaths from any cause | 2 of 44 | 1 of 44 | 88 | NCT02161406 | Trial comparisons |
| Abatacept vs Placebo: Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year | 35 of 44 | 40 of 44 | 88 | NCT02161406 | Trial comparisons |
| Abatacept vs Placebo: serious adverse events | 9 of 44 | 12 of 44 | 88 | NCT02161406 | Trial comparisons |
| Abatacept vs IV Fluid: serious adverse events | 1 of 7 | 0 of 3 | 10 | NCT00442611 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001072
GET https://conductscience.org/api/diseases/v1/HP_0001072/drugs